T he framework for development of new therapies for ischemic stroke has dramatically changed, prompting further consideration of scientific, clinical, and regulatory processes leading to approval of new drugs and devices. For the first time since intravenous thrombolysis was approved for the treatment of acute ischemic stroke (AIS), endovascular thrombectomy (EVT) became an additional standard of care treatment for patients with large vessel occlusions.
T he framework for development of new therapies for ischemic stroke has dramatically changed, prompting further consideration of scientific, clinical, and regulatory processes leading to approval of new drugs and devices. For the first time since intravenous thrombolysis was approved for the treatment of acute ischemic stroke (AIS), endovascular thrombectomy (EVT) became an additional standard of care treatment for patients with large vessel occlusions. 1 Rapid expansion of these revascularization strategies in routine clinical practice altered the landscape for clinical research. Increasingly common use of a wider variety of specific variables and end points is revising the way we study the impact of stroke interventions and resultant outcomes. In AIS, as in other conditions, when new drug therapies transition from phase 3 randomized, controlled trials (RCT) to phase 4 postmarket surveillance studies and registries of extended, real-world evidence, findings emerge that are salient to the development of precision medicine. 2, 3 To maximize the insights gained, it is desirable to optimize trial and registry designs and the way data are collected. Regulatory pathways have also changed, providing novel avenues to promote potential treatments for patients with stroke around the world. Adjunctive strategies and combination therapies from the acute to chronic phases of stroke similarly pose challenges and opportunities. Key stakeholders from academia, industry, and regulatory groups convened at the STAIR (Stroke Treatment Academic Industry Roundtable) X meeting in Washington, DC in October 2017 to deliberate about these recent changes and develop considerations in a workshop devoted to emerging regulatory issues and the evaluation of future stroke treatments.
These recommendations for development and evaluation of new therapies addresses many recent changes because of EVT in AIS while covering future advances from the prehospital to chronic phases of stroke, including various stroke subtypes and novel strategies. Research advances in stroke therapies rapidly evolved to include the next generation of endovascular trials, adjunctive drug use, stem cell therapies, and integration of diagnostic tools such as automated imaging analyses. 4 Combination therapies, novel drug mechanisms, and the use of real-world data for precision medicine elicit discussion and fuel novel considerations in regulatory pathways. Evolution of clinical trial design impacts investigation of new therapies and must be reconciled with United States Food and Drug Administration (FDA) requirements. Recommendations from attendees of this STAIR X workshop address these modern aspects of stroke research and therapeutics development, including strategies to improve and enhance efficiency of this process.
Our recommendations primarily focused on 4 areas (1) variables and surrogate end points, (2) study design paradigms, (3) approval pathways, and (4) novel treatment combinations (Tables I through IV in the online-only Data  Supplement) . Recommendations were established by participation of individuals intimately involved with recent stroke treatment advances, reflecting a diverse array of investigators, sponsors, and regulators. These recommendations mirror contemporaneous STAIR X workshop discussions on expanding thrombectomy populations or indications and the development of neuroprotective treatments.
Variables and Surrogate End Points
The variables used in clinical research studies for development of stroke therapies should be standardized (eg, National Institutes of Health-National Institute of Neurological Disorders and Stroke Common Data Elements), yet the relative hierarchy or prioritization of such variables is dependent on the nature of the trial. 5 In designing a prospective study, the choice of variables and source of such data are key decisions as resources are scarce and additional data
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September 2018 collection of any type adds cost. Investigators are often questioned about the utility of specific variables considering these investments. Many demographics, clinical history variables, metrics of clinical deficits, and imaging data are key prognostic variables routinely acquired in daily practice. Accordingly, they should be included in almost all studies, but efforts should facilitate abstraction directly exported from the medical record. Automated data transfer has rapidly evolved, yet limitations exist, including systematic nomenclature and ontology across variable data sets. For example, the Australian Stroke Clinical Registry outlined several such logistic challenges that emerge when implementing such basic informatics tasks. 6 Seamless data transfer for stroke registries, including subtype classification, remains an elusive goal. 7 Data may be collected from the local site as source documents (eg, anesthesia flowcharts, endovascular procedure reports, or Digital Imaging and Communications in Medicine (DICOM) files of imaging and angiography), centrally archived and reviewed by core laboratories. 8 For many variables, a major value is in the centrally adjudicated reading and not necessarily in the site-reported measure. Other variables may be informative, yet logistics may preclude systematic evaluation. For instance, 30-day in-person neurological deficit outcomes may be difficult to obtain, as it can be cumbersome for patients to make multiple return visits. In contrast, 30-day functional outcomes may be adequately sampled via telephone interview.
Surrogate end points may be used instead of clinical outcomes, yet they must be validated with strong evidence of association with clinical disease, enabling the biomarker to substitute for a clinical outcome. In AIS, biomarker end points have been established in phase 2 drug trials, and arterial reperfusion nearly meets the stringent criteria required to serve as a surrogate for clinical outcomes in phase 3 drug trials. Similarly, in aneurysm embolization device trials, early safety parameters and angiographic occlusion metrics have been used. Biomarkers are more readily accepted if the mechanism of the investigational intervention is understood. For instance, EVT devices are clearly linked with thrombus removal in a large artery supplying blood flow to the brain. Because the relationship between reperfusion of the downstream territory and clinical outcomes is well established in certain patients with AIS based on imaging criteria, time to treatment from last known well, and location of thrombus, use of the Thrombolysis in Cerebral Infarction (TICI) reperfusion scale on postprocedure angiography is a rational technical efficacy outcome measure for EVT. 9 Leading biomarker end points for EVT may either assess technical efficacy for arterial reperfusion or evaluate brain parenchymal imaging (eg, infarct growth) to correlate with clinical outcomes. 10 Proposed surrogate measures or choice of specific parameters would depend on goals of the intended use (eg, potential indication or label), investigational stage (eg, EFS [Early Feasibility Study] versus pivotal clinical trial) and nature of the study (eg, academic/scientific investigation versus pivotal clinical trial for marketing approval). All such considerations for surrogate end points should accompany prospective FDA discussions about suitability of the proposed surrogate during trial design.
For EVT, the nature of the selected variables and potential surrogate end points is predicated on available evidence from prior studies. Robust data are derived from studies of anterior circulation proximal arterial occlusions in the internal carotid artery or middle cerebral artery (MCA), treated within 6 hours and with preprocedure imaging with limited ischemic changes or preserved Alberta Stroke Program Early CT Score (ASPECTS) of ≥6.
11,12 Extrapolation of surrogate measures defined in this context may not be valid outside this population. For instance, data remain limited on the correlations with outcome for TICI reperfusion in subjects with distal arterial occlusions or on the impact of thrombectomy in subjects with large ischemic core volumes or low ASPECTS. 4 An opportunity exists to leverage large data sets such as HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) or VISTA (Virtual International Stroke Trials Archive) to validate biomarkers and surrogates for future studies, where revascularization, imaging features, safety measures, or other end points may be used. [13] [14] [15] For revascularization, successful reperfusion has previously been ascribed to modified TICI score of 2B (mTICI 2B) or greater, denoting cases where >50% of the downstream territory has been linked with better 90-day outcomes on the modified Rankin Scale (mRS). More recent data from HERMES reveals that the expanded TICI (eTICI) scale, including all prior grades for the degree or extent of reperfusion in the downstream territory, is closely correlated with 90-day mRS. 16 Detailed analyses revealed that the threshold of eTICI 2b67, equivalent to the original TICI 2B measure of >67% reperfusion, best approximated good clinical outcomes (mRS score of 0-2). This finding provides a sound basis for a surrogate end point of >eTICI 2b67 for good clinical outcomes. Further analyses of large-scale data such as HERMES may define other angiographic reperfusion metrics such as distal emboli or emboli into new territory that modify the eTICI surrogate for EVT. Similarly, incorporation of time metrics with eTICI reperfusion thresholds may identify the time-dependency of such surrogate end points in future revascularization studies. The prospect of such time-dependent reperfusion metrics will rely on establishing specific and standardized time intervals (eg, time interval from puncture to final eTICI, time from first stent deployment to final eTICI) in EVT. 17, 18 Safety end points may also be assessed using surrogate metrics. For example, the occurrence of symptomatic intracranial hemorrhage within an early period after intervention may indicate long-term safety at 90 days or later. Safety surrogates should be specifically defined rather than use of composite adverse event rates that might obscure informative data. In EVT, specific events such as arterial perforation or dissection should be measured, with prespecified thresholds to evaluate safety. Finally, surrogate end points may be able to prospectively combine efficacy and safety, quantifying the risk-benefit ratio at the study population level.
Future regulatory decisions on stroke treatments may address the standard mRS definitions of clinical outcomes, using alternative approaches to gauge the impact of stroke interventions by comparing the distribution of mRS scores between groups. More recently, the utility-weighted mRS ascribes different weights to specific outcomes, recognizing the variable individual value or impact of certain poststroke disabilities. 19 The utility-weighted mRS is appealing, but needs further validation and should be explored in other populations where the assigned values or subjective weightings differ. The utility weighting in one population may not be applicable to others with differing societal and cultural values. Even the time point of the standard 90-day functional outcome may be reconsidered given numerous logistic challenges, and future strategies may use telephone or internet-based video evaluation, using validated scripts instead of requiring direct physical examinations. [20] [21] [22] The existing clinical trial paradigm that requires 90-day mRS may fuel enrollment bias, as socioeconomic and other factors may promote recruitment of only certain individuals into prospective trials. Premorbid mRS functional status should be considered, when available. Earlier time points for evaluation of patient outcomes may be reasonable as patients may succumb to other illnesses and the impact of acute stroke interventions may be more efficiently reflected by early improvements in clinical deficits. Early National Institutes of Health Stroke Scale improvement or the serial change in neurological deficits from baseline to 24 hours provides an early indication of what might ensue at 90 days. Early epochs for evaluation may pose challenges in some cases, as intubated or other patients may not be evaluable. These considerations will also differ depending on stroke subtype, as lacunar stroke patients or those with basilar artery occlusions rather than anterior circulation lesions may respond differently. Ongoing analyses of large stroke data sets are therefore extremely valuable in defining key variables of interest and outcome measures for those with noninternal carotid artery or MCA occlusions.
Imaging variables require standardization with respect to specific definitions and validation in large data sets before they are used as surrogates. The scientific literature is replete with descriptions of infarct core and penumbra, yet these definitions are dependent on imaging modality (ie, computed tomography [CT] or magnetic resonance imaging [MRI] ) and the parameters (ie, tissue injury or severe hypoperfusion that may predict irreversible injury) used. Infarct core may be variably defined by ASPECTS on CT or MRI, which reflects direct tissue sequelae or injury in the brain, whereas CT or MRI perfusion measures of relative cerebral blood flow reflect severe hypoperfusion that predict subsequent irreversible injury over ensuing hours or days. Although there may be a correlation between ASPECTS and relative cerebral blood flow, they are distinct measures that vary with time duration and hemodynamics. 23, 24 Similarly, the operational penumbral definition on CT or MRI has commonly used a Tmax or time delay threshold of >6 seconds, but it should be remembered that this has been developed solely for internal carotid artery or MCA occlusions and may not be the same if the underlying cause of the arterial occlusion is caused by intracranial atherosclerosis. 25 In addition, there may be a time-dependent relationship between these parameters and tissue viability. 26 Infarct growth should be standardly defined by modality and specific time point. The ability to discern lesions on CT is not the same as with MRI and infarct volumes are dynamic. Other imaging outcome variables, such as hemorrhagic transformation, have been operationally defined, but results vary with CT or MRI. For all imaging measures, utility depends on study design and objectives. RCTs may use a control arm for comparison, yet other study designs require validated comparators. Automated imaging techniques in use or in development for measurement of lesion volume or perfusion abnormalities must demonstrate accuracy and consistency across subjects.
Central definitions for all outcome measures or surrogates is essential to maintain data quality and reliability. Clinical and imaging data may be adjudicated by the local investigator or in central core laboratories. Locally-determined adjudications may be prone to bias and central core laboratory evaluations blinded to other data are now standard. Generalizability may be more realistic when a local investigator is tasked with determining baseline ASPECTS before treatment, yet such readings may be unreliable without proper training and certification. 27 Automated imaging software algorithms may supplant such local determinations, but such approaches include inaccuracies because of artifacts and do not constitute core laboratory evaluations. The choice of core laboratories for evaluation of imaging, angiography, and other data types should incorporate prior experience of the core, infrastructure, and the efficiency of timely determinations apace with trial conduct.
Study Design From RCTs to Registries and Precision Medicine
Stroke study trial design has remained largely unchanged over the past 20 years. Statistical analysis methods for phase 3 RCTs have evolved to include several options for interim analyses, adaptive designs, and Bayesian approaches during study conduct. 28 Although strategic decisions have been debated about noninferiority, superiority, or other comparators, the assumption has been that all therapies simply progress from phase 0 to 4. Registries are another type of clinical data collection that has been used in other medical disciplines, leading to the concept of individualized therapy or precision medicine. AIS treatment that now includes intravenous thrombolysis and EVT is rapidly growing around the world, whereas advances in care and the possibility of expanding indications argues for the use of registries to establish realworld evidence. For investigational therapies, the concept of platform trials has also been promoted. 29 Platform trials include a wide array of candidate therapies that may be simultaneously evaluated, a type of study design that may now be reasonable in AIS. Registries, however, may serve a distinct purpose, as with the role of various clinical research designs from first-in-human, to pilot studies and RCTs where each design provides an avenue to test specific hypotheses or scientific objectives. 30 Registries have numerous limitations, such as the lack of singular hypotheses, attendant sample size calculations, unclear or unplanned statistical analyses, and potential biases, that should be addressed when implemented as a relatively new paradigm in stroke research. 31, 32 Even when advanced statistical designs are used, there are unavoidable selection biases that may skew results when randomization is not used. Registry-based RCTs have recently been introduced as a potential alternative strategy, providing a rational platform for various types of stroke therapies. [31] [32] [33] [34] [35] The TIMING study (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation), focused on the timing of oral
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anticoagulation in AIS because of atrial fibrillation, uses the Swedish Stroke Register, as one of the earliest examples of the registry-based randomized trial in stroke. 36 Regulatory actions are based on the logical structure of available evidence or study design. For AIS, device trials with primary end points targeted toward revascularization measures have supported clearances as tools for thrombus removal and revascularization of patients with AIS. Alternatively, device trials with concurrent controls of best medical therapy and primary end points of 90-day mRS have supported indications for use of the device in stroke treatment in certain patient populations. As new devices are developed, trial designs and primary end points can be tailored to the intended use and patient population.
Evidence from established data sets may provide solid benchmarks for new treatment indications, leveraging outcome data for patients with certain arterial occlusions, low ASPECTS, different demographic profiles, or other characteristics. The extent or volume of required data required to establish new indications or device equivalence remains an open question. For instance, 2 RCTs of EVT in the extended time window were conducted. 37, 38 Many patients were similarly treated with EVT in an extended time window within the Trevo Retriever Registry, and these data might have served a similar purpose as supportive evidence for a single RCT. In the future, the FDA-initiated Coordinated Registry Network for Devices Used for Acute Ischemic Stroke Intervention may be used to collect registry data on AIS, benchmarking comparators for new investigational therapies. The organization, data architecture, prespecified statistical methods, and operational aspects of Devices Used for Acute Ischemic Stroke Intervention are rapidly being developed and will provide a potentially fruitful research environment for emerging therapies. Registries may be useful for existing devices or to establish new indications. For any of these data sources, the quality and validity of the data will be crucial to their usefulness in regulatory actions. The methodology of each data source, such as ensuring consecutive case enrollment, avoidance of bias, use of audits, and central verification are important.
Large-scale data sets that detail key individual variables across subjects provide a wealth of information for precision medicine strategies in stroke. The impact of devices, drugs, and other biologics such as stem cells may be refined through understanding individual patient responses when wide arrays of variables are collected. Imaging may be used to characterize stroke cause, providing an indispensable method to phenotype stroke and develop novel biomarkers. 3 Distinct markers, such as extent of collateral circulation or collateral status, may be used to distinguish acute stroke patients or those with intracranial atherosclerosis. [39] [40] [41] [42] [43] If serial or longitudinal data are available (eg, imaging or clinical status of a given patient at different time points) it is of great value to control for intersubject variation. Big data approaches may address the impact of potentially confounding variables such as baseline ischemic severity and others that are often unpredictable and nonrandomly distributed in RCTs. The costs and lack of ample resources in RCTs have previously limited the extent of data collected or duration of follow-up that may be gleaned from serial evaluations. Recent technology advances, data exchange, and artificial intelligence strategies such as machine learning now provide novel opportunities to study stroke on a much larger scale than ever before. The organization of this big data, access and reproducibility of algorithms must be defined, however.
Approval Pathways
The regulatory process for new stroke treatments has recently evolved. The portfolio of FDA approval pathways is now broader. FDA accepts all valid scientific evidence used in support of device approval, which may include outside the US clinical data. Valid scientific evidence is defined in the regulations as evidence from well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant human experience with a marketed device, from which it can fairly and responsibly be concluded by qualified experts that there is reasonable assurance of the safety and effectiveness of a device under its conditions of use. For example, the Trevo device label expansion was achieved using data generated in the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). 44 The choice of geographic location for a planned study is a major question. Regulatory pathways have recently changed in China, Japan, and the EU, elevating the degree of scrutiny and setting higher standards for clinical research. 45 More premarket studies are being required and the emphasis on postmarketing surveillance has also grown. Many countries are now requiring that dedicated trials be conducted within each country for local regulatory approval. There are some exceptions, such as the example of Japan accepting US data. Industry continues to explore methods leveraging data from outside the United States for FDA applications, given differences in protocols, standards of care, and patient populations. These issues are now relevant to all types of studies, from premarket applications to expansion of indications. There are undoubtedly challenges with differences in systems of care and resources, as reflected in the recent World Stroke Organization roadmap for stroke. Physician medical communities and medical societies should be a better avenue to define such standards than regulatory bodies. Other considerations such as ease of contracting and cost may also influence choice of location for clinical trials. In the United States, academic medical centers often have lengthy contracting processes leading to delays in study initiation and study duration significantly increasing expense for industry. In the last several years, the NIH StrokeNet infrastructure has facilitated multicenter trial conduct in the United States from a budgetary standpoint, suggesting that StrokeNet may be able to help streamline site contracting, enhance recruitment, and reduce time to study completion. 46 For all sponsors, the FDA Pre-Submission program offers a platform for dialogue between industry and regulatory bodies before finalizing the study design. Topics can include specific preclinical performance testing required to support initiation of a clinical study and premarket clearance or approval applications. It has recently become much easier to get such influential feedback during early study stages from both the FDA Center for Devices and Radiological Health and the Center for Drug Evaluation and Research. These changes should encourage companies to conduct US trials. The Center for Devices and Radiological Health Early Feasibility Studies program encourages US trial development by allowing a small number of subjects to evaluate the device design concept with respect to initial clinical safety and device functionality, helping to guide device modifications. The Center for Devices and Radiological Health Breakthrough Devices program created in 2017, previously referred to as the Expedited Access Pathway program, provides additional features to accelerate the regulatory process for devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating human conditions where breakthrough technologies exist without alternatives. The Breakthrough Devices program provides regulatory consultation on novel products to help fast-track protocol design.
Novel Strategies and Regulatory Approval
In stroke, the process and routes for regulatory approval have changed considerably. The advent of numerous industrysponsored registries (eg, STRATIS [Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke], Trevo Retriever Registry) and emergence of the Devices Used for Acute Ischemic Stroke Intervention Coordinated Registry Network that will link numerous registries, creates an opportunity for regulatory approval to expand existing indications and to streamline device trials. 47 For registries, the index of required data elements for a specific action remains an open question. For instance, could a large registry be leveraged to yield an EVT label for treatment of M2 MCA or vertebrobasilar occlusions? The plethora of variables normally considered in stroke treatment creates an extensive set of questions about regulatory approvals. For instance, the consideration of combination therapies where imaging software, drugs, and devices are used together should be addressed. These issues are increasingly complex when there is more than one investigational device as when imaging software is used for perfusion processing, and an endovascular tool is used for revascularization. Drug and device combinations are already being studied in combination, as with adjunctive neuroprotection or different EVT anesthesia methods. Even combined use of endovascular tools and techniques creates complexity, as with stent retrievers and aspiration, use of balloon guide catheters with stent retrievers or treatment of tandem lesions with internal carotid artery angioplasty and stenting with MCA thrombectomy.
The recent success of EVT for AIS has overshadowed consideration of the regulatory process for other stroke types and different phases of stroke care. Unique regulatory considerations for these aspects of stroke care should also be addressed. The regulatory pathways outlined above similarly apply, yet these distinct paradigms offer different challenges. Future issues to be addressed include regulatory implications of systems of care, prehospital interventions, use of mobile stroke units, telemedicine, and direct thrombectomy. Different diagnostic imaging strategies (eg, CT versus MRI, perfusion imaging versus ASPECTS) also require consideration. Even in subacute stroke, there are many neurovascular disorders that may involve endovascular or surgical revascularization strategies, such as treatment of extracranial or intracranial atherosclerosis and the growing experience of surgical therapy for moyamoya syndrome. Concomitant medical management of acute to subacute stroke harbors many areas devoid of evidence where guidelines remain vague. Periprocedural and neurointensive care management of blood pressure demand investigation and studies on postprocedural blood pressure control or alternatively, pressor therapy must be prioritized. Additionally, the role of subacute rehabilitation strategies should be considered in concert with acute stroke. Historically, these entities have been artificially separated despite the overt interaction of acute and subacute interventions. Finally, there are novel treatments for which the mechanisms may either be distinct, multifactorial, or simply unknown. Transcranial direct stimulation, as an example, should be studied considering initial stroke subtype, treatment, and other features. For stem cell therapies, either cell sources or related products, there may be multiple mechanisms and approaches must be implemented to account for such scenarios where unique safety issues and treatment durations vary. For instance, potency assays for stem cells are generally lacking. In sum, there are many potential new stroke treatments where the clinical paradigms and regulatory pathways must build on the current framework focused on AIS. Perhaps the most critical impact of STAIR resides in guiding next steps in translating treatments from laboratory to the bedside around the world, tackling many of these complex issues.
Conclusions
Breakthroughs in the historical impasse to the approval of new stroke treatments have revealed novel challenges in further development and regulatory measures of additional medical, mechanical, or system-related therapies. Data considerations, study design, approval pathways, and new paradigms of stroke care described in this article identify many opportunities to improve and streamline future research.
